gyki 53655 has been researched along with s18986-1 in 1 studies
| Studies (gyki 53655) | Trials (gyki 53655) | Recent Studies (post-2010) (gyki 53655) | Studies (s18986-1) | Trials (s18986-1) | Recent Studies (post-2010) (s18986-1) |
|---|---|---|---|---|---|
| 111 | 0 | 22 | 19 | 0 | 3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Closier, M; Iop, F; Lestage, P; Lockhart, B | 1 |
1 other study(ies) available for gyki 53655 and s18986-1
| Article | Year |
|---|---|
(S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide: (S18986-1) a positive modulator of AMPA receptors enhances (S)-AMPA-mediated [3H]noradrenaline release from rat hippocampal and frontal cortex slices.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Benzodiazepines; Benzothiadiazines; Calcium; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Synergism; Excitatory Amino Acid Antagonists; Frontal Lobe; Hippocampus; In Vitro Techniques; Male; Norepinephrine; Pyrrolidinones; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Stereoisomerism; Tetrodotoxin; Tritium | 2000 |